Guardant Health’s (GH) “Overweight” Rating Reaffirmed at Stephens

Stephens reiterated their overweight rating on shares of Guardant Health (NASDAQ:GH) in a report released on Wednesday morning,Benzinga reports. The brokerage currently has a $55.00 target price on the stock.

Several other equities analysts have also recently issued reports on the company. Raymond James reissued an “outperform” rating and set a $59.00 target price (up from $39.00) on shares of Guardant Health in a research note on Friday, February 21st. Canaccord Genuity Group upped their price objective on shares of Guardant Health from $42.00 to $60.00 and gave the stock a “buy” rating in a report on Monday, February 24th. Barclays assumed coverage on shares of Guardant Health in a research note on Thursday, January 23rd. They set an “overweight” rating and a $60.00 target price on the stock. JPMorgan Chase & Co. raised their price objective on shares of Guardant Health from $50.00 to $55.00 and gave the stock an “overweight” rating in a report on Friday, February 21st. Finally, Piper Sandler increased their target price on Guardant Health from $34.00 to $50.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 26th. Twenty equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $48.95.

Guardant Health Stock Down 4.5 %

Shares of NASDAQ GH opened at $43.14 on Wednesday. The company has a market cap of $5.32 billion, a price-to-earnings ratio of -12.12 and a beta of 1.50. The firm’s fifty day moving average is $44.66 and its 200 day moving average is $34.24. Guardant Health has a 52 week low of $15.81 and a 52 week high of $50.89.

Guardant Health (NASDAQ:GH) last issued its quarterly earnings data on Thursday, February 20th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.15). The firm had revenue of $201.81 million for the quarter, compared to the consensus estimate of $192.50 million. Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. Equities research analysts anticipate that Guardant Health will post -2.9 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of GH. 111 Capital bought a new stake in shares of Guardant Health in the 4th quarter worth $254,000. Polar Asset Management Partners Inc. increased its holdings in Guardant Health by 1,902.2% in the 4th quarter. Polar Asset Management Partners Inc. now owns 454,500 shares of the company’s stock worth $13,885,000 after buying an additional 431,800 shares in the last quarter. GF Fund Management CO. LTD. purchased a new position in Guardant Health in the 4th quarter worth about $79,000. Twinbeech Capital LP bought a new position in Guardant Health during the 4th quarter valued at about $367,000. Finally, Two Sigma Advisers LP boosted its holdings in shares of Guardant Health by 96.7% during the 4th quarter. Two Sigma Advisers LP now owns 2,315,600 shares of the company’s stock valued at $70,742,000 after acquiring an additional 1,138,300 shares during the last quarter. 92.60% of the stock is owned by hedge funds and other institutional investors.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.